Novo Nordisk within touching distance of European obesity market as CHMP recommends approval

The EU Committee for Medicinal Products for Human Use has recommended that Novo Nordisk's obesity drug Wegovy be approved. The pharmaceutical company expects to launch the product in Europe in the second half of 2022.

Photo: Tidsvilde Stine/Ritzau Scanpix

Novo Nordisk has come one step closer to getting its obesity drug Wegovy approved in Europe, as the CHMP has recommended is approval.

The EU Commission still needs to authorize the drug, but this is generally seen as a formality once a CHMP recommendation is in place. According to a Novo Nordisk press release, the company expects this to happen within the next two months.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs